124 related articles for article (PubMed ID: 17504195)
1. Amide derivatives of 2,3-diarylacrylophenone as estrogen receptor binding ligands.
Gupta A; Raghunandan R; Kumar A; Maulik PR; Dwivedy A; Keshri G; Singh MM; Ray S
Med Chem; 2007 May; 3(3):241-53. PubMed ID: 17504195
[TBL] [Abstract][Full Text] [Related]
2. Acyclic amides as estrogen receptor ligands: synthesis, binding, activity and receptor interaction.
Stauffer SR; Sun J; Katzenellenbogen BS; Katzenellenbogen JA
Bioorg Med Chem; 2000 Jun; 8(6):1293-316. PubMed ID: 10896109
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 17alpha-20E-21-(4-substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diols as probes for the estrogen receptor alpha hormone binding domain.
Hanson RN; Lee CY; Friel CJ; Dilis R; Hughes A; DeSombre ER
J Med Chem; 2003 Jul; 46(14):2865-76. PubMed ID: 12825929
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
[TBL] [Abstract][Full Text] [Related]
7. Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties.
Gust R; Lubczyk V
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):57-70. PubMed ID: 12943745
[TBL] [Abstract][Full Text] [Related]
8. Furans with basic side chains: synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha.
Mortensen DS; Rodriguez AL; Sun J; Katzenellenbogen BS; Katzenellenbogen JA
Bioorg Med Chem Lett; 2001 Sep; 11(18):2521-4. PubMed ID: 11549460
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of 3-phenyl-4-phenylvinyl benzopyranones and the corresponding 2,2-dimethyl-benzopyrans with structural similarity to estradiol, as estrogen receptor ligands.
Gupta A; Raghunandan R; Kumar A; Maulik PR; Dwivedyc A; Keshri G; Singh MM; Ray S
Med Chem; 2007 Sep; 3(5):446-54. PubMed ID: 17897069
[TBL] [Abstract][Full Text] [Related]
10. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor.
Schmidt JM; Tremblay GB; Plastina MA; Ma F; Bhal neé Basra S; Feher M; Dunn-Dufault R; Redden PR
Bioorg Med Chem; 2005 Mar; 13(5):1819-28. PubMed ID: 15776560
[TBL] [Abstract][Full Text] [Related]
12. Amide derivatives of 9,11-seco-estra-1,3,5(10)-trien-11-oic acid as modified orally active estrogen agonists with moderate antagonistic activity.
Negi AS; Chaturvedi D; Gupta A; Ray S; Dwivedy A; Singh MM
Bioorg Med Chem Lett; 2005 Jan; 15(1):99-102. PubMed ID: 15582419
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor ligands: a patent review update.
Paterni I; Bertini S; Granchi C; Macchia M; Minutolo F
Expert Opin Ther Pat; 2013 Oct; 23(10):1247-71. PubMed ID: 23713677
[TBL] [Abstract][Full Text] [Related]
14. Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs.
Kym PR; Anstead GM; Pinney KG; Wilson SR; Katzenellenbogen JA
J Med Chem; 1993 Nov; 36(24):3910-22. PubMed ID: 8254621
[TBL] [Abstract][Full Text] [Related]
15. Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.
Zheng Y; Zhu M; Srinivasan S; Nwachukwu JC; Cavett V; Min J; Carlson KE; Wang P; Dong C; Katzenellenbogen JA; Nettles KW; Zhou HB
ChemMedChem; 2012 Jun; 7(6):1094-100. PubMed ID: 22517684
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-substituted 3,4-diarylsalicylaldoximes on estrogen receptors alpha and beta.
Minutolo F; Antonello M; Bertini S; Rapposelli S; Rossello A; Sheng S; Carlson KE; Katzenellenbogen JA; Macchia M
Bioorg Med Chem; 2003 Apr; 11(7):1247-57. PubMed ID: 12628652
[TBL] [Abstract][Full Text] [Related]
17. De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.
Schmidt JM; Mercure J; Tremblay GB; Pagé M; Kalbakji A; Feher M; Dunn-Dufault R; Peter MG; Redden PR
J Med Chem; 2003 Apr; 46(8):1408-18. PubMed ID: 12672240
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
19. Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists.
Stauffer SR; Huang YR; Aron ZD; Coletta CJ; Sun J; Katzenellenbogen BS; Katzenellenbogen JA
Bioorg Med Chem; 2001 Jan; 9(1):151-61. PubMed ID: 11197335
[TBL] [Abstract][Full Text] [Related]
20. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
